Anti-PD-1 (programmed cell death 1) Abs and anti-PD-L1 (programmed death ligand 1) Abs, as immune checkpoint inhibitors, block the binding between PD-L1 on cancer cells and PD-1 on T cells [54]. This evidence concerns the gene PDCD1 and cancer.